Literature DB >> 18515795

Pancreatic neuroendocrine tumors (PNETs): incidence, prognosis and recent trend toward improved survival.

T R Halfdanarson1, K G Rabe, J Rubin, G M Petersen.   

Abstract

BACKGROUND: Pancreatic neuroendocrine tumors (PNETs) are uncommon neoplasms that can present with symptoms of hormone overproduction. We evaluated the incidence, prognosis, and temporal trends of PNETs. PATIENTS AND METHODS: We analyzed all cases of PNETs registered in the Surveillance, Epidemiology, and End Results database from 1973 to 2000. Age-adjusted incidence and survival rates were calculated and survival trends over time were evaluated.
RESULTS: We identified 1483 cases of PNETs. The crude annual incidence per 1,000,000 was 1.8 in females and 2.6 in males and increased with advancing age. The incidence increased over the study period. Most patients (90.8%) had nonfunctional tumors. Advanced stage, higher grade, and age were the strongest predictors of worse survival. Patients with functional tumors had better outcomes than patients with nonfunctional tumors in both univariate and multivariate analysis (P = 0.004). Survival time increased over the period from 1973 to 2000. No differences were seen in the distribution of stage or age at diagnosis among time periods.
CONCLUSION: PNETs are uncommon neoplasms but the incidence may be increasing. Age, grade, stage, and functional status predict survival in patients with PNETs. Survival has improved over time, but this is not explained by earlier diagnosis or stage migration.

Entities:  

Mesh:

Year:  2008        PMID: 18515795      PMCID: PMC2735065          DOI: 10.1093/annonc/mdn351

Source DB:  PubMed          Journal:  Ann Oncol        ISSN: 0923-7534            Impact factor:   32.976


  27 in total

1.  Aggressive surgery improves long-term survival in neuroendocrine pancreatic tumors: an institutional experience.

Authors:  Paulus G Schurr; Tim Strate; Kim Rese; Jussuf T Kaifi; Uta Reichelt; Susanne Petri; Helge Kleinhans; Emre F Yekebas; Jakob R Izbicki
Journal:  Ann Surg       Date:  2007-02       Impact factor: 12.969

2.  Islet cell carcinoma of the pancreas.

Authors:  A L Cubilla; S I Hajdu
Journal:  Arch Pathol       Date:  1975-04

Review 3.  Somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine tumors.

Authors:  Thierry Delaunoit; Joseph Rubin; Florence Neczyporenko; Charles Erlichman; Timothy J Hobday
Journal:  Mayo Clin Proc       Date:  2005-04       Impact factor: 7.616

Review 4.  Rationale for the use of somatostatin analogs as antitumor agents.

Authors:  C Susini; L Buscail
Journal:  Ann Oncol       Date:  2006-06-26       Impact factor: 32.976

5.  The frequency of gastrointestinal endocrine tumours in a well-defined population--Northern Ireland 1970-1985.

Authors:  R G Watson; C F Johnston; M M O'Hare; J R Anderson; B G Wilson; J S Collins; J M Sloan; K D Buchanan
Journal:  Q J Med       Date:  1989-07

6.  Epidemiology of pancreatic cancer in Connecticut.

Authors:  R E Moldow; R R Connelly
Journal:  Gastroenterology       Date:  1968-12       Impact factor: 22.682

7.  Neuroendocrine pancreatic tumors. Clinical findings in a prospective study of 84 patients.

Authors:  B Eriksson; K Oberg; B Skogseid
Journal:  Acta Oncol       Date:  1989       Impact factor: 4.089

8.  Differences in survival by histologic type of pancreatic cancer.

Authors:  Megan Dann Fesinmeyer; Melissa A Austin; Christopher I Li; Anneclaire J De Roos; Deborah J Bowen
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2005-07       Impact factor: 4.254

Review 9.  Hepatic surgery for metastases from neuroendocrine tumors.

Authors:  Juan M Sarmiento; Florencia G Que
Journal:  Surg Oncol Clin N Am       Date:  2003-01       Impact factor: 3.495

10.  Cytological differentiation of asymptomatic pancreatic islet cell tumours in autopsy material.

Authors:  L Grimelius; G T Hultquist; B Stenkvist
Journal:  Virchows Arch A Pathol Anat Histol       Date:  1975
View more
  238 in total

Review 1.  Sunitinib in pancreatic neuroendocrine tumors.

Authors:  Eric Raymond; Pascal Hammel; Chantal Dreyer; Christian Maatescu; Olivia Hentic; Philippe Ruszniewski; Sandrine Faivre
Journal:  Target Oncol       Date:  2012-06-02       Impact factor: 4.493

2.  A randomized phase II study of everolimus for advanced pancreatic neuroendocrine tumors in Chinese patients.

Authors:  Jun Yao; Jian-yao Wang; Yi Liu; Bin Wang; Ying-xue Li; Ru Zhang; Li-sheng Wang; Lei Liu
Journal:  Med Oncol       Date:  2014-11-14       Impact factor: 3.064

Review 3.  Well-differentiated pancreatic neuroendocrine tumors: from genetics to therapy.

Authors:  Roeland F de Wilde; Barish H Edil; Ralph H Hruban; Anirban Maitra
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2012-02-07       Impact factor: 46.802

4.  Surgical treatment of pancreatic endocrine tumours in Italy: results of a prospective multicentre study of 262 cases.

Authors:  Alessandro Zerbi; Vanessa Capitanio; Letizia Boninsegna; Claudio Pasquali; Guido Rindi; Gianfranco Delle Fave; Marco Del Chiaro; Riccardo Casadei; Massimo Falconi
Journal:  Langenbecks Arch Surg       Date:  2010-09-21       Impact factor: 3.445

5.  Diagnosis of pancreatic neuroendocrine tumors and the role of endoscopic ultrasound.

Authors:  Linda S Lee
Journal:  Gastroenterol Hepatol (N Y)       Date:  2010-08

Review 6.  Status and future directions in the management of pancreatic cancer: potential impact of nanotechnology.

Authors:  Catherine M Sielaff; Shaker A Mousa
Journal:  J Cancer Res Clin Oncol       Date:  2018-05-02       Impact factor: 4.553

Review 7.  Update on pancreatic neuroendocrine tumors.

Authors:  Logan R McKenna; Barish H Edil
Journal:  Gland Surg       Date:  2014-11

Review 8.  Practical management and treatment of pancreatic neuroendocrine tumors.

Authors:  Naoko Iwahashi Kondo; Yasuharu Ikeda
Journal:  Gland Surg       Date:  2014-11

Review 9.  Learning experiences with sunitinib continuous daily dosing in patients with pancreatic neuroendocrine tumours.

Authors:  E Raymond; S Faivre
Journal:  Curr Oncol       Date:  2014-12       Impact factor: 3.677

10.  Peptide Receptor Radionuclide Therapy Outcomes in a North American Cohort With Metastatic Well-Differentiated Neuroendocrine Tumors.

Authors:  Nancy Sharma; Boris G Naraev; Eric G Engelman; M Bridget Zimmerman; David L Bushnell; Thomas M OʼDorisio; M Sue OʼDorisio; Yusuf Menda; Jan Müller-Brand; James R Howe; Thorvardur R Halfdanarson
Journal:  Pancreas       Date:  2017-02       Impact factor: 3.327

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.